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We have designed a glycodendritic structure, BH30sucMan, that blocks the interaction between dendritic
cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) and Ebola virus (EBOV)
envelope. BH30sucMan inhibits DC-SIGN-mediated EBOV infection at nanomolar concentrations.
BH30sucMan may counteract important steps of the infective process of EBOV and, potentially, of microor-
ganisms shown to exploit DC-SIGN for cell entry and infection.
Ebola virus (EBOV) causes hemorrhagic fever and is con-
sidered to be one of the most lethal pathogens known. The risk
of a widespread epidemic episode, or even its potential use in
bioterrorism, has stimulated research on the agent and the
development of vaccine programs (18). Due to its extraordi-
nary virulence, EBOV is classified as a biosafety level 4 patho-
gen; however, the generation of pseudotyped recombinant ret-
roviral particles has recently allowed the exploration of
important aspects of EBOV biology using biosafety level 2
facilities (21). Despite these efforts, there is no specific cure for
EBOV infection.
Our group and others (1, 17) have previously demonstrated
that EBOV binds to C-type lectins dendritic cell-specific inter-
cellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)
and liver/lymph node SIGN (L-SIGN) and utilizes these mol-
ecules as mediators to gain access to certain cell types. Fur-
thermore, DC-SIGN and L-SIGN can act as trans-receptors to
efficiently capture infective particles and transmit the infection
to susceptible cells (1). DC-SIGN, originally cloned as a hu-
man immunodeficiency virus (HIV) gp120-binding protein (7),
is expressed exclusively on immature dendritic cells and con-
fers upon these cells the ability to facilitate, in trans, HIV
infection of activated CD4 T cells (8). L-SIGN is a closely
related molecule expressed on the surface of endothelial cells
in the liver, lymph node sinuses, and placental villi (3). DC-
SIGN and L-SIGN bind ligands containing oligomannose gly-
cans through the C-terminal carbohydrate recognition domain.
It is highly likely that EBOV, in a manner similar to that of
HIV, subverts the physiological role of these C-type lectins to
achieve important steps in its infectious process, these mole-
cules being critical for the initial steps of viral infection at the
mucosal level and subsequent dissemination throughout the
body. Therefore, DC- and L-SIGN can be considered potential
new targets for the design of compounds acting as viral entry
inhibitors. The low affinity of carbohydrate interactions, com-
pensated for in nature by the multivalent presentation of car-
bohydrate units, has encouraged the design of carbohydrate
multivalent structures to interfere with biological processes in
which carbohydrates are involved. Among these multivalent
systems, glycodendrimers are one of the most popular systems
(4), and they have been used previously in several processes,
including blockage of viral receptors (13, 15). Previous works
with glycodendritic structures, based on the hyperbranched
polymer BoltornH30 (Perstorp Specialty Chemicals), have
shown a number of advantages, including low cytotoxicity, high
solubility in physiological media, and relatively low cost (2).
In order to inhibit EBOV DC-SIGN interaction, we have
designed a glycodendritic structure based on BoltornH30 (Fig.
1), presenting 32 mannose units linked through a succinyl
spacer, BH30sucMan. We tested this compound in an experi-
mental model using an EBOV-GP-pseudotyped lentivirus (1).
Pseudotyped viral vectors have been successfully used in a wide
variety of experimental applications (16), including character-
ization of the receptors used by EBOV (1, 5, 6, 17, 19, 21).
The lentiviral vector pNL4-3.Luc.R-E-, obtained from
Nathaniel Landau (11) (through the AIDS Research and Ref-
erence Reagent Program, Division of AIDS, National Institute
of Allergy and Infectious Diseases, National Institutes of
Health), was used for production of vesicular stomatitis virus G
and EBOV Zaire GP pseudotypes (1) in a transient transfec-
tion protocol using 293T cells as previously described (20). The
expression plasmid for the GP of the Zaire strain of EBOV
(i.e., EBOV-GP) was kindly provided by A. Sanchez (Centers
for Disease Control and Prevention) (21). BH30sucMan was
prepared as described elsewhere (2). Jurkat cells stably trans-
duced with DC-SIGN were infected with EBOV-GP-
pseudotyped lentiviral vectors expressing luciferase using a
multiplicity of infection of 0.1. A range of concentrations of
BH30sucMan was added simultaneously along with the control
compound BH30sucL (without mannoses) (Fig. 1). After 48 h,
cells were lysed and assayed for luciferase expression. The 50%
inhibitory concentrations (IC50) were calculated with Graph-
pad Prism software version 3.0. The inhibitory activity of
BH30sucMan for the in trans function of DC-SIGN was stud-
ied on K562 erythroleukemia cells stably expressing DC-SIGN
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(14). Cells were incubated by rotation for 60 min at room
temperature with supernatants containing Ebola Zaire-
pseudotyped retroviruses in the presence or absence of
BH30sucMan (500 nM) and controls. After this step, cells were
extensively washed with phosphate-buffered saline–1 mM
CaCl2–0.5% bovine serum albumin, resuspended in fresh me-
dium, and plated onto HeLa cell monolayers. After 48 h, K562
cells were removed, the monolayer of HeLa cells was washed
twice, and luciferase activity was measured.
Results of our experiments showed that BH30sucMan was
able to selectively inhibit DC-SIGN-mediated EBOV infection
in an efficient dose-dependent manner (IC50, 337 nM), whereas
it did not affect infection mediated by a DC-SIGN-indepen-
dent viral envelope such as vesicular stomatitis virus G (1).
Infection was also inhibited by the monosaccharide -methyl-
D-mannopyranoside in a dose-dependent manner with an IC50
of 1.27 mM (data not shown). The control structure, BH30sucL,
which does not present sugar units, only showed a limited
effect at concentrations beyond 105 M, which is most likely
explained by nonspecific interactions with receptors at the cell
surface (Fig. 2). Similar results were obtained in parallel ex-
periments by using L-SIGN-expressing cells (data not shown).
As a further proof of the specific action of the glycodendritic
structure, BH30sucMan did not show any inhibitory effect in
FIG. 1. Structure of BoltornH30 (BH30) (top) and schematic representation of BH30sucMan and BH30sucL (bottom).
FIG. 2. Inhibition of DC-SIGN-mediated EBOV-GP pseudotyped viruses in cis, using Jurkat cells expressing DC-SIGN and BH30sucMan or
BH30sucL. Results are shown as the proportion of inhibition in comparison to control (no compound), and the values correspond to the means
of three experiments  standard error of the mean.
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infection experiments using DC-SIGN-negative cell lines, such
as HeLa, which are known to be susceptible to EBOV infection
(data not shown). In the experiments in trans, in which a more
complex series of events such as internalization and presenta-
tion of the viral particle to susceptible cells can take place (12),
BH30sucMan also showed a significant reduction of DC-
SIGN-mediated infection in trans at levels comparable to the
inhibition shown in cis (Fig. 3).
We have shown that BH30sucMan is a potent inhibitor of
EBOV infection mediated by DC-SIGN both in cis (Fig. 2) and
in trans (Fig. 3), presumably due to the same mechanisms of
inhibiting the interaction between the lectin and the viral en-
velope. A carbohydrate-dependent inhibitory effect has been
demonstrated in these experiments; also, a multivalent effect of
two orders of magnitude is shown, since monovalent mannose
was able to inhibit this interaction but at millimolar concen-
trations.
Blocking EBOV interaction with lectin receptors in the mu-
cosal and endothelial territories is a reasonable goal and also a
model for other microorganisms such as HIV (8), cytomega-
lovirus (10), or Mycobacterium tuberculosis (9), any of which
could potentially exploit a similar mechanism. Additionally,
the use of these glycodendritic structures will allow us to better
understand the molecular basis of this interaction as well as the
design of more potent and selective inhibitors.
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FIG. 3. Inhibition of infection of EBOV-GP pseudotyped viruses
mediated in trans by DC-SIGN. K562 cells (negative control) and
K562-expressing DC-SIGN (K562-DC) were used to bind and transfer
viral particles to HeLa cells in the presence or absence of
BH30sucMan and the anti-DC-SIGN monoclonal antibody MR-1 (14).
One representative experiment out of three is shown.
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